A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2015 Based on the results of this trial, sublingual desmopressin [Nocdurna] orally disintegrating tablets were approved in Canada for the treatment of nocturia in adults, according to a Ferring Canada media release.
    • 06 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; Parent trial: NCT00477490).
    • 01 Apr 2012 Results published in Neurourology and Urodynamics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top